SHR8058 eye drops + saline eye drops.
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment of Dry Eye Disease With Meibomian Gland Dysfunction
Conditions
Treatment of Dry Eye Disease With Meibomian Gland Dysfunction
Trial Timeline
Feb 4, 2021 → Sep 7, 2021
NCT ID
NCT05515471About SHR8058 eye drops + saline eye drops.
SHR8058 eye drops + saline eye drops. is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Treatment of Dry Eye Disease With Meibomian Gland Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT05515471. Target conditions include Treatment of Dry Eye Disease With Meibomian Gland Dysfunction.
What happened to similar drugs?
3 of 20 similar drugs in Treatment of Dry Eye Disease With Meibomian Gland Dysfunction were approved
Approved (3) Terminated (4) Active (13)
🔄HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05515471 | Phase 3 | Completed |
Competing Products
20 competing products in Treatment of Dry Eye Disease With Meibomian Gland Dysfunction